JAZ Is Required for Interlukin-3 Withdrawal-Induced Apoptosis by Directly Activating p53.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 1445-1445
Author(s):  
Mingli Yang ◽  
Jingxin Qiu ◽  
Ying Li ◽  
Jinghua Jia ◽  
W. Stratford May

Abstract By screening a murine interleukin-3 (IL-3)-dependent myeloid cell cDNA library, we previously identified JAZ (Just Another Zinc Finger Protein), a novel zinc finger (ZF) protein that localizes in the nucleus and preferentially binds dsRNA rather than DNA. Forced overexpression of JAZ induces apoptosis but the mechanism was not known. JAZ is differentially expressed in CD34+ primary human and mouse bone marrow cells including mononuclear myeloid and lymphoid cells but not in multinuclear megakaryocytes, indicating that JAZ may function in hematopoietic progenitor cells. Since IL-3 withdrawal induces apoptosis in factor-dependent myeloid and lymphoid cells, we tested whether endogenous JAZ is involved. Hematopoietic cell lines including murine NFS/N1.H7, 32D myeloid and BaF3 lymphoid cells were deprived of IL-3 for 0, 0.5, 1, 2, 4, 6, 8, 12, 24 and/or 48 hr. Results reveal that JAZ expression is upregulated prior to induction of cell death. While a role for p53 in hematopoietic progenitor cell response to apoptosis-inducing stress has been postulated, the mechanism is not clear. Therefore, we assessed whether p53 expression or activation can be affected by JAZ. Results reveal that in association with JAZ upregulation, IL-3 withdrawal also induces p53 expression and importantly, up-regulates its transcriptional activity as assessed by increased BAX expression. To verify p53 dependency, p53-deficient murine M1 and human K562 leukemic cells were also tested. These p53-deficient cells are highly insensitive to serum withdrawal-induced cell death. Importantly, siRNA-mediated ‘knock-down’ of endogenous JAZ (by 70–80%) attenuates stress-induced cell death in NFS/N1.H7 but not M1 cells. These data point to a necessary role for JAZ in IL-3 or growth factor withdrawal-induced hematopoietic cell death in a p53-dependent manner. Further analysis using co-immunoprecipitation studies indicates that endogenous JAZ and p53 associate upon IL-3 withdrawal. Furthermore, using p53+/+ and p53−/− isogenic murine embryonic fibroblasts (MEFs), we clearly show that JAZ not only directly interacts with p53 but also stimulates its transcriptional activity, resulting in mediation/acceleration of stress-activated, p53-dependent apoptosis. Therefore, we propose that the nuclear factor JAZ may be a novel regulator of p53 in the hematopoietic cell response to stress leading to apoptosis. Since only about 15% of hematologic-malignancies express mutant (transcriptionally inactive) p53, it may be possible to therapeutically target wild-type p53 through a mechanism involving JAZ.

1994 ◽  
Vol 14 (8) ◽  
pp. 5099-5107 ◽  
Author(s):  
N Koyano-Nakagawa ◽  
J Nishida ◽  
D Baldwin ◽  
K Arai ◽  
T Yokota

The CT/GC-rich region (-76 to -47) is one transcriptional regulatory region of the interleukin-3 (IL-3) gene which confers basic transcriptional activity and responds to trans-activation by human T-cell leukemia virus type I-encoded Tax. We isolated three types of cDNAs encoding Cys2/His2-type zinc finger proteins that bind to this region. Two were identical to known transcription factors, EGR1 and EGR2, and the other clone, named DB1, encoded a novel protein of 516 amino acids with six zinc finger motifs. DB1 mRNA was present in human tissues, ubiquitously. Two constitutive transcripts of 4.0 and 4.8 kb in length were present in Jurkat cells. Electrophoretic mobility shift assay, with specific antibodies, showed that DB1 constitutively binds to this region whereas EGR1 binds in a T-cell activation-dependent manner. Overexpression of DB1 in Jurkat cells had no detectable effect on the transcription activity of the IL-3 promoter, in a transient-transfection assay. EGR1 and EGR2 increased IL-3 promoter activity when the transfected cells were stimulated with phorbol-12-myristate-13-acetate and A23187. When DB1 was cotransfected with a Tax expression vector, transcription activity of the IL-3 promoter induced by Tax was significantly increased, while EGR1 and EGR2 were without effect. These results suggest that EGR1 has a role in inducible transcription of the IL-3 gene, while DB1 sustains basal transcriptional activity and also cooperates with Tax to activate the IL-3 promoter.


Cells ◽  
2022 ◽  
Vol 11 (2) ◽  
pp. 278
Author(s):  
John M. Baust ◽  
Kristi K. Snyder ◽  
Robert G. Van Buskirk ◽  
John G. Baust

The development and use of complex cell-based products in clinical and discovery science continues to grow at an unprecedented pace. To this end, cryopreservation plays a critical role, serving as an enabling process, providing on-demand access to biological material, facilitating large scale production, storage, and distribution of living materials. Despite serving a critical role and substantial improvements over the last several decades, cryopreservation often remains a bottleneck impacting numerous areas including cell therapy, tissue engineering, and tissue banking. Studies have illustrated the impact and benefit of controlling cryopreservation-induced delayed-onset cell death (CIDOCD) through various “front end” strategies, such as specialized media, new cryoprotective agents, and molecular control during cryopreservation. While proving highly successful, a substantial level of cell death and loss of cell function remains associated with cryopreservation. Recently, we focused on developing technologies (RevitalICE™) designed to reduce the impact of CIDOCD through buffering the cell stress response during the post-thaw recovery phase in an effort to improve the recovery of previously cryopreserved samples. In this study, we investigated the impact of modulating apoptotic caspase activation, oxidative stress, unfolded protein response, and free radical damage in the initial 24 h post-thaw on overall cell survival. Human hematopoietic progenitor cells in vitro cryopreserved in both traditional extracellular-type and intracellular-type cryopreservation freeze media were utilized as a model cell system to assess impact on survival. Our findings demonstrated that through the modulation of several of these pathways, improvements in cell recovery were obtained, regardless of the freeze media and dimethyl sulfoxide concentration utilized. Specifically, through the use of oxidative stress inhibitors, an average increase of 20% in overall viability was observed. Furthermore, the results demonstrated that by using the post-thaw recovery reagent on samples cryopreserved in intracellular-type media (Unisol™), improvements in overall cell survival approaching 80% of non-frozen controls were attained. While improvements in overall survival were obtained, an assessment on the impact of specific cell subpopulations and functionality remains to be completed. While work remains, these results represent an important step forward in the development of improved cryopreservation processes for use in discovery science, and commercial and clinical settings.


Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 4894-4894 ◽  
Author(s):  
Anilkumar Gopalakrishnapillai ◽  
Sonali P Barwe ◽  
E. Anders Kolb

Abstract Acute myeloid leukemia (AML) accounts for 18% of childhood leukemia diagnoses. Although, the 5-year survival rate for children with AML is estimated at 64%, novel therapeutic options are required to improve the outcome for certain subsets of AML that are refractory. The contribution of epigenetic modifiers to the pathogenesis of AML in children is becoming evident following the discovery of mutations in patients, which affect DNA and/or histone methylation. Although DNA methyltransferase (DNMT) inhibitors have been approved in AML, their efficacy as single agents has been limited. This could be due to the crosstalk between DNA methylation and histone modifications that together regulate gene expression. This raises the possibility that optimal re-expression of silenced tumor suppressor genes in AML requires treatment with both DNMT and histone deacetylase (HDAC) inhibitors. We evaluated the effect of a combination of DNA methyltransferase inhibitor azacytidine with HDAC inhibitors panobinostat or romidepsin on the viability of three pediatric AML cell lines- MV4;11 (expressing wild-type p53), THP-1 (with no detectable p53 mRNA) and AML-193 (with mutated p53). We observed that azacytidine as a single-agent only moderately reduced cell viability of MV4;11 cells (IC50 – 7 uM), and it failed to induce cell death in THP-1 and AML-193 cells. However, azacytidine in combination with panobinostat and romidepsin was more effective at reducing cell viability in MV4;11 and THP-1 cells (with a combination index of 0.5 to 0.6). AML-193 cells were almost insensitive to cell death induced by the combination treatment. This suggests that p53 is required for induction of cell death by azacytidine and panobinostat/romidepsin combination. Although THP-1 cells have no detectable p53 expression, other studies have reported the upregulation of p53 following stimulation with nitric oxide or 7-oxysterols. The effect on cell viability in THP-1 cells is likely due to the reexpression of silenced p53 in these cells. Taken together, our data suggests that combining azacytidine with panobinostat/romidepsin induces synergistic cell death in a p53-dependent manner. Disclosures: No relevant conflicts of interest to declare.


2013 ◽  
Vol 13 (1) ◽  
pp. 123 ◽  
Author(s):  
Amanda Nogueira-Pedro ◽  
Thalyta Aparecida Munhoz Cesário ◽  
Carolina Dias ◽  
Clarice Silvia Taemi Origassa ◽  
Lilian Piñero Marcolin Eça ◽  
...  

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Vanessa Silva Silveira ◽  
Kleiton Silva Borges ◽  
Verena Silva Santos ◽  
Mariana Tannús Ruckert ◽  
Gabriela Maciel Vieira ◽  
...  

Abstract SHOC2 scaffold protein has been mainly related to oncogenic ERK signaling through the RAS-SHOC2-PP1 phosphatase complex. In leukemic cells however, SHOC2 upregulation has been previously related to an increased 5-year event-free survival of pediatric pre-B acute lymphoid leukemia, suggesting that SHOC2 could be a potential prognostic marker. To address such paradoxical function, our study investigated how SHOC2 impact leukemic cells drug response. Our transcriptome analysis has shown that SHOC2 can modulate the DNA-damage mediated by p53. Notably, upon genetic inhibition of SHOC2 we observed a significant impairment of p53 expression, which in turn, leads to the blockage of key apoptotic molecules. To confirm the specificity of DNA-damage related modulation, several anti-leukemic drugs has been tested and we did confirm that the proposed mechanism impairs cell death upon daunorubicin-induced DNA damage of human lymphoid cells. In conclusion, our study uncovers new insights into SHOC2 function and reveals that this scaffold protein may be essential to activate a novel mechanism of p53-induced cell death in pre-B lymphoid cells.


1988 ◽  
Vol 33 (5) ◽  
pp. 983-988 ◽  
Author(s):  
Gerald M. Segal ◽  
Joseph W. Eschbach ◽  
Joan C. Egrie ◽  
Terri Stueve ◽  
John W. Adamson

2020 ◽  
Vol 2020 ◽  
pp. 1-12
Author(s):  
Xiaoya Xi ◽  
Tao He

Breast cancer (BCa) is the most common aggressive tumor with limited curative therapeutic options available among women worldwide. JK184 is a potent Hedgehog inhibitor that regulates the glioma-dependent transcriptional activity. Although some studies have indicated that JK184 can kill BCa cells, it remains unclear whether there are any events that limit the use of JK184 in BCa therapy. Here, we report that JK184 intervention induces BCa cell death involving the dysregulation of autophagy in a dose- and time-dependent manner. The induction of autophagy compromises the antiproliferative effect of JK184. Mechanistically, JK184 induces autophagy via inhibiting the Akt/mTOR pathway in BCa cells. Taken together, our findings unravel a novel mechanism for JK184 treatment in BCa, suggesting that JK184 in combination with autophagy inhibitor may be a potential therapeutic strategy for the clinical treatment of BCa.


1994 ◽  
Vol 14 (8) ◽  
pp. 5099-5107
Author(s):  
N Koyano-Nakagawa ◽  
J Nishida ◽  
D Baldwin ◽  
K Arai ◽  
T Yokota

The CT/GC-rich region (-76 to -47) is one transcriptional regulatory region of the interleukin-3 (IL-3) gene which confers basic transcriptional activity and responds to trans-activation by human T-cell leukemia virus type I-encoded Tax. We isolated three types of cDNAs encoding Cys2/His2-type zinc finger proteins that bind to this region. Two were identical to known transcription factors, EGR1 and EGR2, and the other clone, named DB1, encoded a novel protein of 516 amino acids with six zinc finger motifs. DB1 mRNA was present in human tissues, ubiquitously. Two constitutive transcripts of 4.0 and 4.8 kb in length were present in Jurkat cells. Electrophoretic mobility shift assay, with specific antibodies, showed that DB1 constitutively binds to this region whereas EGR1 binds in a T-cell activation-dependent manner. Overexpression of DB1 in Jurkat cells had no detectable effect on the transcription activity of the IL-3 promoter, in a transient-transfection assay. EGR1 and EGR2 increased IL-3 promoter activity when the transfected cells were stimulated with phorbol-12-myristate-13-acetate and A23187. When DB1 was cotransfected with a Tax expression vector, transcription activity of the IL-3 promoter induced by Tax was significantly increased, while EGR1 and EGR2 were without effect. These results suggest that EGR1 has a role in inducible transcription of the IL-3 gene, while DB1 sustains basal transcriptional activity and also cooperates with Tax to activate the IL-3 promoter.


Sign in / Sign up

Export Citation Format

Share Document